ESALY News and Press, Eisai Co. Ltd. ADR From 09/28/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid a notable positive session for the major equity indices, Biogen (NASDAQ: BIIB ) really got the party started with a massive 37% boost in the early afternoon session on Wednesday. Biogen disclosed very encouraging r...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: pathdoc / Shutterstock.com Acumen Pharmaceuticals (NASDAQ: ABOS ) stock is rocketing higher on Wednesday but it’s not due to any news from the company. Instead, investors have Biogen  (NAS...

Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday. The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating A...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, we have a win-win for everyone except the short sellers. Biogen (NASDAQ: BIIB ) and Japanese pharmaceutical firm Eisai (OTCMKTS: ESALY ) are co-developing an experimental Alzheimer’s disease drug c...

Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint TOKYO, Sept 28, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced positive topline results from Eisai's large global Phase 3 confirmatory Clarity AD clinical trial of le...

Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis TOKYO, Sept 26, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today th...

Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma TOKYO and RAHWAY, N.J., Sept 12, 2022 - (JCN Newswire) - ...

Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022 TOKYO, Sept 12, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today results from a post hoc analysis of three randomized, pivotal, P...

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022 TOKYO, Sept 6, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the Europea...

Summary Q2 results are on the table and Idorsia could convince with encouraging developments in its pipeline and its initial commercial efforts with QUVIVIQ (Daridorexant) and PIVLAZ (Clazosentan). The Swiss and Canadian health authorities are supposed to give their feedback on QU...